TABLE 3.
Distribution of the study population by their vaccination status and history of testing PCR-positive and their correlation with the four-tested immune response biomarkers.
| N = 952 (valid%) | Anti-S IgG N = 952 |
P-value | Anti-N IgG N = 952 |
P-value | Neutralizing IgG N = 952 |
P-value | T-cell response N = 925 |
P-value | |||||
| <357.5 | ≥357.5 | <146.5 | ≥146.5 | <172.0 | ≥172.0 |
Yes 353 (38.2%) |
No 572 (61.8%) |
||||||
| Vaccination against SARS-CoV-2 | <0.001 | <0.001 | <0.001 | 0.001 | |||||||||
| Not vaccinated | 13 (1.4) | 9 (69.2) | 4 (30.8) | 9 (69.2) | 4 (30.8) | 9 (69.2) | 4 (30.8) | 4 (30.8) | 9 (69.2) | ||||
| Only one dose | 9 (0.9) | 4 (44.4) | 5 (55.6) | 3 (33.3) | 6 (66.7) | 5 (55.6) | 4 (44.4) | 4 (44.4) | 5 (55.6) | ||||
| Two doses | 192 (20.2) | 96 (50.0) | 96 (50.0) | 126 (65.6) | 66 (34.4) | 89 (46.4) | 103 (53.6) | 66 (35.5) | 120 (64.5) | ||||
| One booster dose (three doses) | 714 (75.2) | 366 (51.3) | 348 (48.7) | 326 (45.7) | 388 (54.3) | 371 (52.0) | 343 (48.0) | 263 (37.8) | 433 (62.1) | ||||
| Two booster dose (four doses) | 21 (2.2) | 1 (4.8) | 20 (95.2) | 12 (57.1) | 9 (42.9) | 1 (4.8) | 20 (95.2) | 16 (84.2) | 3 (15.8) | ||||
| Missing | 3 | 2 | |||||||||||
| Boosted vs. not boosted (n = 927)1 | 1.00 | <0.001 | 0.296 | 0.384 | |||||||||
| Not boosted (two doses only) (mean duration: 159.6 ± 71.8 days)2 | 192 (20.7) | 96 (50.0) | 96 (50.0) | 126 (65.6) | 66 (34.4) | 89 (46.4) | 103 (53.6) | 66 (35.5) | 120 (64.5) | ||||
| Boosted (mean duration: 70.2 ± 24.8 days)2 | 735 (79.3) | 367 (49.9) | 368 (50.1) | 338 (46.0) | 397 (54.0) | 372 (50.6) | 363 (49.4) | 279 (39.0) | 436 (61.1) | ||||
| Vaccine type | <0.001 | <0.001 | <0.001 | <0.001 | |||||||||
| BBIBP-CorV only (mean duration: 87.5 51.0 days)2 | 874 (92.2) | 461 (52.7) | 413 (47.3) | 420 (48.1) | 454 (51.9) | 459 (52.5) | 415 (47.5) | 309 (36.4) | 540 (63.6) | ||||
| rAd26-S + rAd5-S only (mean duration: 210 ± 13.0 days)2 | 14 (1.5) | 0 (0.0) | 14 (100) | 14 (100) | 0 (0.0) | 0 (0.0) | 14 (100) | 5 (35.7) | 9 (64.3) | ||||
| BNT162b2 only (mean duration: 106.7 ± 12.5 days)2 | 3 (0.3) | 0 (0.0) | 3 (100) | 3 (100) | 0 (0.0) | 0 (0.0) | 3 (100) | 3 (100) | 0 (0.0) | ||||
| Started BBIBP-CorV boosted with BNT162b2 (mean duration: 70.2 ± 69.2 days)2 | 38 (4.0) | 5 (13.2) | 33 (86.8) | 24 (63.2) | 14 (36.8) | 5 (13.2) | 33 (86.8) | 27 (73.0) | 10 (27.0) | ||||
| Mixed vaccine type3 (mean duration: 154.7 ± 64.4 days)2 | 7 (0.7) | 1 (14.3) | 6 (85.7) | 6 (85.7) | 1 (14.3) | 2 (28.6) | 5 (71.4) | 5 (71.4) | 2 (28.6) | ||||
| Not vaccinated (8) or the first dose was after blood collection (5) | 13 (1.4) | 9 (69.2) | 4 (30.8) | 9 (69.2) | 4 (30.8) | 9 (69.2) | 4 (30.8) | 4 (30.8) | 9 (69.2) | ||||
| Missing | 3 | 2 | |||||||||||
| Duration since last vaccine dose to blood collection, median (IQR), mean ± (SD)4 | 79.0 (56.0–96.0) 89.2 (±54.5) days |
0.492 | <0.001 | 0.873 | <0.001 | ||||||||
| 1–14 days | 19 (2.0) | 11 (57.9) | 8 (42.1) | 16 (84.2) | 3 (15.8) | 8 (42.1) | 11 (57.9) | 14 (77.8) | 4 (22.2) | ||||
| 15–30 days | 34 (3.6) | 14 (41.2) | 20 (58.8) | 16 (47.1) | 18 (52.9) | 16 (47.1) | 18 (52.9) | 16 (48.5) | 17 (51.1) | ||||
| 31–60 days | 256 (27.0) | 122 (47.7) | 134 (52.3) | 93 (36.3) | 163 (63.7) | 126 (49.2) | 130 (50.8) | 69 (28.0) | 177 (72.0) | ||||
| 61–295 days | 624 (65.8) | 319 (51.1) | 305 (48.9) | 339 (54.3) | 285 (45.7) | 315 (50.5) | 309 (49.5) | 248 (40.6) | 363 (59.4) | ||||
| T-cell response (n = 925) | <0.001 | 0.975 | <0.001 | ||||||||||
| Yes | 353 (38.2%) | 144 (40.7) | 209 (59.3) | 178 (50.3) | 175 (49.7) | 138 (39.0) | 215 (61.0) | – | – | ||||
| No | 572 (61.8%) | 321 (56.1) | 251 (43.9) | 287 (50.2) | 285 (49.8) | 326 (57.0) | 246 (43.0) | – | – | ||||
1Excluding not vaccinated or received only one dose.
2Mean time duration post-last vaccine dose.
3Started with rAd26-S + rAd5-S and boosted with BNT162b2 or BBIBP-CorV (n = 5) or first dose was BBIBP-CorV and second dose BNT162b2 or rAd26-S + rAd5-S (n = 2).
4Included only received at least one vaccine dose.